Cannabigerol – CBG
CBG was first isolated in 1964 by Raphael Mechoulam’s laboratory. It is non-psychoactive and usually appears in relatively low concentrations in the cannabis plant. Relatively few studies have sought to investigate the pharmacological actions of this compound, and research is currently limited to studies in vitro and experiments on rodents. Preliminary research suggests that CBG may stimulate a range of receptors important for pain, inflammation and heat sensitization. In addition, CBG, like CBD, is thought to elevate levels of anandamide available for neurotransmission by inhibiting the reuptake of anandamide.
Cannabidiolic acid - CBD-a
CBD-a is the non-psychoactive precursor to CBD. It requires decarboxylation to become CBD, a process that can occur naturally as the plant ages from exposure to light and heat, but is more often accelerated by heating. Because most CBD products on the market are heated in some way they contain very little CBDa. We know very little about CBDa relative to CBD, but preclinical research has demonstrated potential anti-emetic, anti-proliferative activity.